Log in to save to my catalogue

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_12089368

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

About this item

Full title

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2025-05, Vol.16 (1), p.4638-12, Article 4638

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Clinical responses with chimeric antigen receptor (CAR) T cells are encouraging, but primary resistance and relapse after therapy prevent durable remission in many patients with cancer, with apoptosis resistance in cancer cells that limits killing by CAR T cells being a potential cause. Here we aim to boost tumor cell apoptosis induced by CAR T cel...

Alternative Titles

Full title

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_12089368

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_12089368

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-025-59818-8

How to access this item